Clinical Trials Directory

Trials / Unknown

UnknownNCT02691624

Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

Lymphoscintigraphy is a noninvasive,accurate and effective imaging modality. In this study, it is used to investigate the imaging characteristics of patients'upper limb lymphatic drainage before operation, and the influence of operation on it.

Detailed description

The global burden of breast cancer continues to increase largely because of the aging and growth of the world population. More than 1.38 million women worldwide were estimated to be diagnosed with breast cancer in 2008, accounting for 23% of all diagnosed cancers in women. Given that the 5-year survival rate for breast cancer is now 90%, experiencing breast cancer is ultimately about quality of life. Women treated for breast cancer are facing a life-time risk of developing lymphedema, a chronic condition that occurs in up to 40% of this population and negatively affects breast cancer survivors' quality of life. It's becoming more and more important to do more research on the breast cancer-related lymphedema. Axillary reverse mapping (ARM) is a technique used to map arm lymphatic drainage during axillary lymph node dissection (ALND) and/or sentinel lymph node dissection (SLND). It's necessary for the investigators to understand the participants' upper limb lymphatic drainage before operation and what the investigators have done on it during operation. It can be easy to understand the influence of operation on the participants' upper limb lymphatic drainage, the possibility and safety of reserving lymph nodes draining the upper extremity lymph.

Conditions

Timeline

Start date
2015-10-01
Primary completion
2016-05-01
Completion
2021-12-01
First posted
2016-02-25
Last updated
2021-12-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02691624. Inclusion in this directory is not an endorsement.